Examkin

Question

Difficulty: HardPharmacologic Interventions

A 72-year-old man with a 6-year history of Parkinson disease is brought to the neurology clinic by his wife due to new-onset visual hallucinations over the past two weeks. He reports seeing unfamiliar people standing in his living room, which is causing him significant distress. His motor symptoms (tremor and bradykinesia) have been well-controlled recently. His current daily medication regimen includes carbidopa-levodopa, pramipexole, amantadine, and trihexyphenidyl. Vital signs are within normal limits. Neurologic examination shows mild resting tremor and rigidity, unchanged from his previous visit. Laboratory studies, including a urinalysis and basic metabolic panel, are unremarkable.

According to the standard step-wise approach for managing Parkinson disease-related psychosis, arrange the following pharmacologic modifications in the correct sequential order (from the first step to the final step).

  1. 1Discontinue trihexyphenidyl
  2. 2Discontinue amantadine
  3. 3Discontinue pramipexole
  4. 4Initiate quetiapine

Answer

The correct sequential order is to first discontinue trihexyphenidyl, then discontinue amantadine, then discontinue pramipexole, and finally initiate quetiapine if symptoms persist.
The management of Parkinson disease psychosis involves a step-wise approach to minimize medication-induced delirium while attempting to preserve motor function. The first step is always to rule out general medical conditions (e.g., infections). Once ruled out, a sequential reduction of adjunctive Parkinson medications is performed in reverse order of their motor efficacy and forward order of their side effect profile. Anticholinergics (trihexyphenidyl) are the most deliriogenic and provide the least motor benefit, making them the first to be discontinued. If symptoms persist, amantadine is discontinued next. This is followed by MAO-B inhibitors (if present) and then dopamine agonists (pramipexole). Only if psychosis persists despite the withdrawal of these adjunctive therapies (or if severe motor deterioration prevents their withdrawal) should an atypical antipsychotic with low extrapyramidal risk, such as quetiapine or pimavanserin, be initiated.

Step-by-Step Solution

1
Identify the primary clinical problem
The patient is experiencing new-onset visual hallucinations (psychosis) induced by Parkinson disease medications, with secondary causes (e.g., infection, metabolic derangements) already ruled out.
Visual hallucinations are a common adverse effect of dopaminergic and anticholinergic therapies in advanced Parkinson disease and must be managed systematically.
2
Determine the first step in the medication taper protocol
Discontinue the anticholinergic agent (trihexyphenidyl).
Anticholinergics carry the highest risk for cognitive impairment and hallucinations with the least motor benefit, making them the absolute first target for discontinuation.
3
Determine the next sequential medications to withdraw if symptoms persist
Discontinue amantadine, followed by the dopamine agonist (pramipexole).
Amantadine has high neuropsychiatric toxicity and should be removed next. Dopamine agonists are tapered after amantadine because they provide greater motor control, even though they frequently trigger psychosis.
4
Determine the final intervention for refractory psychosis
Initiate an atypical antipsychotic (quetiapine).
If psychosis persists despite discontinuing adjunctive therapies, a low-potency atypical antipsychotic without significant D2 antagonism is added to avoid worsening motor symptoms.

Key Concept

The step-wise pharmacologic management of Parkinson disease psychosis involves sequentially discontinuing adjunctive medications in reverse order of motor efficacy (anticholinergics, then amantadine, then MAO-B inhibitors, then dopamine agonists) before initiating an atypical antipsychotic.
Rate this question

Topics

Pharmacologic Interventions

More questions from this topic